The biotech sector is witnessing a shift as public markets begin to reopen for initial public offerings (IPOs) after several years of subdued activity, according to JPMorgan's top EMEA healthcare investment bankers interviewed by CNBC [1]. However, investor selectivity has increased significantly compared to the pandemic-era boom, with only the highest-quality biotech companies attracting interest for IPOs [1]. Many biotech firms are now pursuing a dual-track process, simultaneously preparing for IPOs while engaging with potential acquirers, reflecting the competitive landscape for exits [1].
Big Pharma companies are under mounting pressure to replenish their drug pipelines ahead of major patent expirations expected later this decade and into the early 2030s [1]. This urgency has led to a resurgence in healthcare dealmaking, particularly in biopharma, where large pharmaceutical firms are well-funded and increasingly willing to make substantial acquisitions [1]. Strategic buyers are actively seeking opportunities to deploy capital, and shareholders are showing greater support for mergers and acquisitions as a growth strategy, according to Juha Anjala and Roy Wouters, co-heads of JPMorgan's EMEA healthcare investment banking [1].
The market for top-tier biotech assets—especially those with differentiated technology or exposure to major therapeutic areas such as oncology, metabolic diseases, and infectious diseases—has become more competitive [1]. In some instances, companies ready to go public are being acquired by large pharmaceutical groups before reaching the public markets, a trend JPMorgan's bankers have recently advised on [1].
Despite the improved exit environment for biotech founders and investors compared to a year or two ago, the rebound is not broad-based. Boards and investment committees are exercising greater scrutiny over transactions, and private capital is becoming more concentrated, leading to a bifurcation in the market [1]. As the IPO window reopens, Big Pharma's pursuit of growth through M&A is expected to continue setting the pace for the sector [1].
CONCLUSION
The reopening of the biotech IPO market signals renewed opportunities, but heightened investor selectivity and ongoing Big Pharma M&A activity continue to shape the sector's landscape. While high-quality biotech firms benefit from a more competitive exit market, the overall recovery remains uneven, with strategic acquisitions likely to dominate in the near term.